HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

08 سبتمبر 2021 05:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference

07 سبتمبر 2021 03:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces Selection of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs

06 سبتمبر 2021 01:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer

25 أغسطس 2021 19:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Selected as Constituent of Certain Hang Seng Indexes

22 أغسطس 2021 19:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China

08 أغسطس 2021 19:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer

27 يوليو 2021 19:00:00 بحسب Nasdaq GlobeNewswire

Stabilizing Actions and End of Stabilization Period in connection with the Global Offering

23 يوليو 2021 06:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED’s Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency

15 يوليو 2021 19:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca

13 يوليو 2021 01:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global Offering

12 يوليو 2021 08:52:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL 295 in Patients with Advanced Solid Tumors in China

05 يوليو 2021 18:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED to Announce 2021 Half-Year Financial Results

02 يوليو 2021 03:30:00 بحسب Nasdaq GlobeNewswire

U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

01 يوليو 2021 05:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces the Closing of the Global Offering and the Primary Listing in Hong Kong

30 يونيو 2021 04:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces Pricing of Global Offering

23 يونيو 2021 09:22:40 بحسب Nasdaq GlobeNewswire

HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations

22 يونيو 2021 12:15:57 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda® in China) for Advanced Pancreatic Neuroendocrine Tumors

18 يونيو 2021 10:24:42 بحسب Nasdaq GlobeNewswire

HUTCHMED Launches Hong Kong Initial Public Offering

17 يونيو 2021 18:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program

20 مايو 2021 01:00:00 بحسب Nasdaq GlobeNewswire